Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension Study

What Was Tested

The paper reports a study of Semaglutide, published as a randomized controlled trial.

To evaluate changes in glycaemic control following semaglutide discontinuation in adults with Type 1 diabetes and obesity who completed the ADJUST-T1D randomised controlled trial.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

Analyses included participants previously randomised to semaglutide who discontinued treatment (n = 16) and participants previously randomised to placebo who did not receive a glucagon-like peptide-1 receptor agonist during follow-up (n = 22).

Changes in CGM-derived metrics from Week 26 to the extension phase were compared using Wilcoxon rank-sum tests with Benjamini-Hochberg adjustment.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A placebo (an inactive look-alike) gave the Semaglutide group a baseline to be compared against.

The timeline in the abstract includes 12 weeks.

Continuous glucose monitoring (CGM) data were collected during a 12-week extension phase after the ADJUST-T1D trial.

Analysis of covariance (ANCOVA) adjusting for Week 26 values was performed as a sensitivity analysis.

What Was Measured

The subject headings attached to it are Blood Glucose, Continuous Glucose Monitoring, Diabetes Mellitus, Type 1, Glycated Hemoglobin, Glycemic Control, Hypoglycemia and Hypoglycemic Agents.

The authors tagged it with the keywords GLP‐1 receptor agonist, Type 1 diabetes, automated insulin delivery and glycaemic variability.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Semaglutide over 12 weeks.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Semaglutide compound page, all human trials.